{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,7]],"date-time":"2026-08-07T17:20:59Z","timestamp":1786123259423,"version":"build-2736575974"},"reference-count":149,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Molecular and Cellular Endocrinology"],"published-print":{"date-parts":[[2026,11]]},"DOI":"10.1016\/j.mce.2026.112876","type":"journal-article","created":{"date-parts":[[2026,7,27]],"date-time":"2026-07-27T23:21:23Z","timestamp":1785194483000},"page":"112876","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Small molecule ligands for the melanocortin-4 receptor: pharmacology, biased signaling, and pharmacoperone potential"],"prefix":"10.1016","volume":"621","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4737-749X","authenticated-orcid":false,"given":"Ya-Xiong","family":"Tao","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ren-Lei","family":"Ji","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.mce.2026.112876_bib1","doi-asserted-by":"crossref","first-page":"2555","DOI":"10.1021\/jm00132a010","article-title":"Potent and prolonged acting cyclic lactam analogues of alpha-melanotropin: design based on molecular dynamics","volume":"32","author":"Al-Obeidi","year":"1989","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.mce.2026.112876_bib2","doi-asserted-by":"crossref","first-page":"3413","DOI":"10.1021\/ja00191a044","article-title":"Design of a new class of superpotent cyclic \u03b1-melanotropins based on quenched dynamic simulations","volume":"111","author":"Al-Obeidi","year":"1989","journal-title":"J. Am. Chem. Soc."},{"key":"10.1016\/j.mce.2026.112876_bib3","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1021\/jm0255522","article-title":"Structure-activity relationship of (1-aryl-2-piperazinylethyl)piperazines: antagonists for the AGRP\/melanocortin receptor binding","volume":"46","author":"Arasasingham","year":"2003","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.mce.2026.112876_bib4","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1210\/clinem\/dgac547","article-title":"Changing the name of diabetes insipidus: a Position Statement of the Working Group for Renaming Diabetes Insipidus","volume":"108","author":"Arima","year":"2022","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"10.1016\/j.mce.2026.112876_bib5","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1016\/j.cell.2005.08.035","article-title":"Divergence of melanocortin pathways in the control of food intake and energy expenditure","volume":"123","author":"Balthasar","year":"2005","journal-title":"Cell"},{"key":"10.1016\/j.mce.2026.112876_bib6","doi-asserted-by":"crossref","first-page":"1376","DOI":"10.1056\/NEJMoa2208754","article-title":"Dersimelagon in erythropoietic protoporphyrias","volume":"388","author":"Balwani","year":"2023","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.mce.2026.112876_bib7","doi-asserted-by":"crossref","first-page":"1165","DOI":"10.3390\/jcm14041165","article-title":"Melanocortin-4 receptor antagonism inhibits colorectal and anaplastic thyroid cancer in vitro and in vivo","volume":"14","author":"Bandini","year":"2025","journal-title":"J. Clin. Med."},{"key":"10.1016\/j.mce.2026.112876_bib8","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1016\/S1877-1173(09)88004-6","article-title":"The melanocortin-1 receptor gene polymorphism and association with human skin cancer","volume":"88","author":"Beaumont","year":"2009","journal-title":"Prog. Mol. Biol. Transl. Sci."},{"key":"10.1016\/j.mce.2026.112876_bib9","doi-asserted-by":"crossref","first-page":"1020","DOI":"10.1016\/j.peptides.2007.02.011","article-title":"Potent and selective agonists of \u03b1-melanotropin (\u03b1MSH) action at human melanocortin receptor 5; linear analogs of \u03b1-melanotropin","volume":"28","author":"Bednarek","year":"2007","journal-title":"Peptides"},{"key":"10.1016\/j.mce.2026.112876_bib10","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1016\/B978-0-12-386933-3.00004-2","article-title":"Melanocortin-3 receptors and metabolic homeostasis","volume":"114","author":"Begriche","year":"2013","journal-title":"Prog. Mol. Biol. Transl. Sci."},{"key":"10.1016\/j.mce.2026.112876_bib11","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1681\/ASN.2005080854","article-title":"Pharmacologic chaperones as a potential treatment for X-linked nephrogenic diabetes insipidus","volume":"17","author":"Bernier","year":"2006","journal-title":"J. Am. Soc. Nephrol."},{"key":"10.1016\/j.mce.2026.112876_bib12","doi-asserted-by":"crossref","first-page":"2960","DOI":"10.1021\/cr050984g","article-title":"Nonpeptidic ligands for peptide-activated G protein-coupled receptors","volume":"107","author":"Blakeney","year":"2007","journal-title":"Chem. Rev."},{"key":"10.1016\/j.mce.2026.112876_bib13","doi-asserted-by":"crossref","first-page":"1358","DOI":"10.1373\/clinchem.2005.047886","article-title":"Six novel mutations in the proopiomelanocortin and melanocortin receptor 4 genes in severely obese adults living in southern Italy","volume":"51","author":"Buono","year":"2005","journal-title":"Clin. Chem."},{"key":"10.1016\/j.mce.2026.112876_bib14","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1124\/pr.56.1.1","article-title":"Targeting melanocortin receptors as a novel strategy to control inflammation","volume":"56","author":"Catania","year":"2004","journal-title":"Pharmacol. Rev."},{"key":"10.1016\/j.mce.2026.112876_bib15","first-page":"95","article-title":"Involvement of the melanocortin MC4 receptor in stress-related behavior in rodents","volume":"474","author":"Chaki","year":"2003","journal-title":"Our J Pharmacology"},{"key":"10.1016\/j.mce.2026.112876_bib16","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1016\/j.pbb.2005.11.001","article-title":"MCL0042: a nonpeptidic MC4 receptor antagonist and serotonin reuptake inhibitor with anxiolytic- and antidepressant-like activity","volume":"82","author":"Chaki","year":"2005","journal-title":"Pharmacol. Biochem. Behav."},{"key":"10.1016\/j.mce.2026.112876_bib17","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1016\/S0079-6468(06)45503-X","article-title":"Recent progress toward nonpeptide ligands for the melanocortin-4 receptor","volume":"45","author":"Chen","year":"2007","journal-title":"Prog. Med. Chem."},{"key":"10.1016\/j.mce.2026.112876_bib18","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1016\/S0092-8674(00)80467-5","article-title":"Exocrine gland dysfunction in MC5-R-deficient mice: evidence for coordinated regulation of exocrine gland function by melanocortin peptides","volume":"91","author":"Chen","year":"1997","journal-title":"Cell"},{"key":"10.1016\/j.mce.2026.112876_bib19","doi-asserted-by":"crossref","first-page":"2517","DOI":"10.1681\/ASN.2006091024","article-title":"Peripheral administration of the melanocortin-4 receptor antagonist NBI-12i ameliorates uremia-associated cachexia in mice","volume":"18","author":"Cheung","year":"2007","journal-title":"J. Am. Soc. Nephrol."},{"key":"10.1016\/j.mce.2026.112876_bib20","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1210\/endrev\/bnab016","article-title":"Congenital adrenal hyperplasia-current insights in pathophysiology, diagnostics, and management","volume":"43","author":"Claahsen-van der Grinten","year":"2022","journal-title":"Endocr. Rev."},{"key":"10.1016\/j.mce.2026.112876_bib21","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1038\/s41591-018-0015-9","article-title":"MC4R agonism promotes durable weight loss in patients with leptin receptor deficiency","volume":"24","author":"Cl\u00e9ment","year":"2018","journal-title":"Nat. Med."},{"key":"10.1016\/j.mce.2026.112876_bib22","doi-asserted-by":"crossref","first-page":"736","DOI":"10.1210\/er.2006-0034","article-title":"Studies on the physiological functions of the melanocortin system","volume":"27","author":"Cone","year":"2006","journal-title":"Endocr. Rev."},{"key":"10.1016\/j.mce.2026.112876_bib23","first-page":"287","article-title":"The melanocortin receptors: agonists, antagonists, and the hormonal control of pigmentation","volume":"51","author":"Cone","year":"1996","journal-title":"Recent Prog. Horm. Res."},{"key":"10.1016\/j.mce.2026.112876_bib24","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1124\/pr.59.3.2","article-title":"G protein-coupled receptor trafficking in health and disease: lessons learned to prepare for therapeutic mutant rescue in vivo","volume":"59","author":"Conn","year":"2007","journal-title":"Pharmacol. Rev."},{"key":"10.1016\/j.mce.2026.112876_bib25","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1016\/j.tem.2006.05.005","article-title":"Cachexia: lessons from melanocortin antagonism","volume":"17","author":"DeBoer","year":"2006","journal-title":"Trends Endocrinol. Metabol."},{"key":"10.1016\/j.mce.2026.112876_bib26","doi-asserted-by":"crossref","first-page":"2468","DOI":"10.1016\/j.bbadis.2017.03.018","article-title":"Polymorphisms and mutations in the melanocortin-3 receptor and their relation to human obesity","volume":"1863","author":"Demidowich","year":"2017","journal-title":"Biochim. Biophys. Acta Mol. Basis Dis."},{"key":"10.1016\/j.mce.2026.112876_bib27","doi-asserted-by":"crossref","first-page":"1599","DOI":"10.1007\/s40265-019-01187-w","article-title":"Bremelanotide: first approval","volume":"79","author":"Dhillon","year":"2019","journal-title":"Drugs"},{"key":"10.1016\/j.mce.2026.112876_bib28","doi-asserted-by":"crossref","first-page":"5577","DOI":"10.1021\/acs.jmedchem.0c02041","article-title":"Discovery of nanomolar melanocortin-3 receptor (MC3R)-selective small molecule pyrrolidine bis-cyclic guanidine agonist compounds via a high-throughput \u201cunbiased\" screening campaign","volume":"64","author":"Doering","year":"2021","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.mce.2026.112876_bib29","doi-asserted-by":"crossref","first-page":"1777","DOI":"10.1016\/0024-3205(96)00160-9","article-title":"Evaluation of melanotan-II, a superpotent cyclic melanotropic peptide in a pilot phase-I clinical study","volume":"58","author":"Dorr","year":"1996","journal-title":"Life Sci."},{"key":"10.1016\/j.mce.2026.112876_bib30","doi-asserted-by":"crossref","DOI":"10.1016\/j.molmet.2025.102301","article-title":"Cross-species studies implicate the melanocortin 3 receptor more strongly in the control of pubertal development than energy balance","volume":"103","author":"Duckett","year":"2026","journal-title":"Mol. Metabol."},{"key":"10.1016\/j.mce.2026.112876_bib31","doi-asserted-by":"crossref","first-page":"e1580","DOI":"10.1210\/clinem\/dgad373","article-title":"Prevalence of deleterious variants in MC3R in patients with constitutional delay of growth and puberty","volume":"108","author":"Duckett","year":"2023","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"10.1016\/j.mce.2026.112876_bib32","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1016\/S1877-1173(09)88005-8","article-title":"The molecular basis of adrenocorticotrophin resistance syndrome","volume":"88","author":"Elias","year":"2009","journal-title":"Prog. Mol. Biol. Transl. Sci."},{"key":"10.1016\/j.mce.2026.112876_bib33","doi-asserted-by":"crossref","first-page":"2414","DOI":"10.1016\/j.bbadis.2017.03.020","article-title":"Bench-top to clinical therapies: a review of melanocortin ligands from 1954 to 2016","volume":"1863","author":"Ericson","year":"2017","journal-title":"Biochim. Biophys. Acta Mol. Basis Dis."},{"key":"10.1016\/j.mce.2026.112876_bib34","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1038\/385165a0","article-title":"Role of melanocortinergic neurons in feeding and the agouti obesity syndrome","volume":"385","author":"Fan","year":"1997","journal-title":"Nature"},{"key":"10.1016\/j.mce.2026.112876_bib35","doi-asserted-by":"crossref","first-page":"3268","DOI":"10.1111\/j.1582-4934.2009.00726.x","article-title":"Functional characterization and pharmacological rescue of melanocortin-4 receptor mutations identified from obese patients","volume":"13","author":"Fan","year":"2009","journal-title":"J. Cell Mol. Med."},{"key":"10.1016\/j.mce.2026.112876_bib36","doi-asserted-by":"crossref","first-page":"1085","DOI":"10.1056\/NEJMoa022050","article-title":"Clinical spectrum of obesity and mutations in the melanocortin 4 receptor gene","volume":"348","author":"Farooqi","year":"2003","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.mce.2026.112876_bib37","doi-asserted-by":"crossref","DOI":"10.1530\/EC-22-0338","article-title":"Identification of a novel specific small-molecule melanocortin-2-receptor antagonist","volume":"11","author":"Forfar","year":"2022","journal-title":"Endocr Connect"},{"key":"10.1016\/j.mce.2026.112876_bib38","doi-asserted-by":"crossref","first-page":"1131","DOI":"10.2174\/156802607780906663","article-title":"Melanocortin-4 receptor antagonists as potential therapeutics in the treatment of cachexia","volume":"7","author":"Foster","year":"2007","journal-title":"Curr. Top. Med. Chem."},{"key":"10.1016\/j.mce.2026.112876_bib39","doi-asserted-by":"crossref","first-page":"1699","DOI":"10.1002\/anie.199416991","article-title":"Peptidomimetics\u2014Tailored enzyme inhibitors","volume":"33","author":"Gante","year":"1994","journal-title":"Angew. Chem., Int. Ed. Engl."},{"key":"10.1016\/j.mce.2026.112876_bib40","doi-asserted-by":"crossref","first-page":"3195","DOI":"10.1021\/acs.jmedchem.2c02012","article-title":"Discovery of the potent and selective MC4R antagonist PF-07258669 for the potential treatment of appetite loss","volume":"66","author":"Garnsey","year":"2023","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.mce.2026.112876_bib41","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1016\/j.cmet.2017.10.016","article-title":"LEAP2 is an endogenous antagonist of the ghrelin receptor","volume":"27","author":"Ge","year":"2018","journal-title":"Cell Metab."},{"key":"10.1016\/j.mce.2026.112876_bib42","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.pharmthera.2005.06.022","article-title":"Targeting melanocortin receptors as potential novel therapeutics","volume":"111","author":"Getting","year":"2006","journal-title":"Pharmacol. Ther."},{"key":"10.1016\/j.mce.2026.112876_bib43","doi-asserted-by":"crossref","first-page":"eaat0866","DOI":"10.1126\/sciadv.aat0866","article-title":"Regulation of energy rheostasis by the melanocortin-3 receptor","volume":"4","author":"Ghamari-Langroudi","year":"2018","journal-title":"Sci. Adv."},{"key":"10.1016\/j.mce.2026.112876_bib44","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1056\/NEJMoa0803085","article-title":"Modulation of blood pressure by central melanocortinergic pathways","volume":"360","author":"Greenfield","year":"2009","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.mce.2026.112876_bib45","doi-asserted-by":"crossref","first-page":"4998","DOI":"10.1021\/jm000211e","article-title":"D-Amino acid scan of \u03b3-melanocyte-stimulating hormone: importance of Trp8 on human MC3 receptor selectivity","volume":"43","author":"Grieco","year":"2000","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.mce.2026.112876_bib46","doi-asserted-by":"crossref","first-page":"1075","DOI":"10.1006\/bbrc.2002.6739","article-title":"Design and synthesis of highly potent and selective melanotropin analogues of SHU9119 modified at position 6","volume":"292","author":"Grieco","year":"2002","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"10.1016\/j.mce.2026.112876_bib47","doi-asserted-by":"crossref","first-page":"8208","DOI":"10.1021\/acs.jmedchem.1c01856","article-title":"A small-molecule oral agonist of the human glucagon-like peptide-1 receptor","volume":"65","author":"Griffith","year":"2022","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.mce.2026.112876_bib48","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1021\/acsptsci.1c00270","article-title":"Development of a therapeutic peptide for cachexia suggests a platform approach for drug-like peptides","volume":"5","author":"Gruber","year":"2022","journal-title":"ACS Pharmacol. Transl. Sci."},{"key":"10.1016\/j.mce.2026.112876_bib49","doi-asserted-by":"crossref","first-page":"1889","DOI":"10.1016\/0024-3205(87)90047-6","article-title":"Topical application of a melanotropic peptide induces systemic follicular melanogenesis","volume":"40","author":"Hadley","year":"1987","journal-title":"Life Sci."},{"key":"10.1016\/j.mce.2026.112876_bib50","doi-asserted-by":"crossref","first-page":"921","DOI":"10.1016\/j.peptides.2005.01.029","article-title":"Melanocortin peptide therapeutics: historical milestones, clinical studies and commercialization","volume":"27","author":"Hadley","year":"2006","journal-title":"Peptides"},{"key":"10.1016\/j.mce.2026.112876_bib51","doi-asserted-by":"crossref","first-page":"1123","DOI":"10.1021\/jm025600i","article-title":"Discovery of tyrosine-based potent and selective melanocortin-1 receptor small-molecule agonists with anti-inflammatory properties","volume":"46","author":"Herpin","year":"2003","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.mce.2026.112876_bib52","doi-asserted-by":"crossref","first-page":"1176","DOI":"10.1038\/s41422-021-00569-8","article-title":"Structures of active melanocortin-4 receptor-Gs-protein complexes with NDP-\u03b1-MSH and setmelanotide","volume":"31","author":"Heyder","year":"2021","journal-title":"Cell Res."},{"key":"10.1016\/j.mce.2026.112876_bib53","doi-asserted-by":"crossref","first-page":"1483","DOI":"10.1210\/jcem.84.4.5728","article-title":"Several mutations in the melanocortin-4 receptor gene including a nonsense and a frameshift mutation associated with dominantly inherited obesity in humans","volume":"84","author":"Hinney","year":"1999","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"10.1016\/j.mce.2026.112876_bib54","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1016\/B978-0-12-386933-3.00005-4","article-title":"Melanocortin-4 receptor in energy homeostasis and obesity pathogenesis","volume":"114","author":"Hinney","year":"2013","journal-title":"Prog. Mol. Biol. Transl. Sci."},{"key":"10.1016\/j.mce.2026.112876_bib55","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1146\/annurev.ge.24.120190.001025","article-title":"The LDL receptor locus in familial hypercholesterolemia: mutational analysis of a membrane protein","volume":"24","author":"Hobbs","year":"1990","journal-title":"Annu. Rev. Genet."},{"key":"10.1016\/j.mce.2026.112876_bib56","doi-asserted-by":"crossref","first-page":"2496","DOI":"10.1016\/j.bbadis.2017.03.001","article-title":"Pharmacological chaperones for the misfolded melanocortin-4 receptor associated with human obesity","volume":"1863","author":"Huang","year":"2017","journal-title":"Biochim. Biophys. Acta Mol. Basis Dis."},{"key":"10.1016\/j.mce.2026.112876_bib57","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1530\/JME-12-0161","article-title":"Pleiotropic functions of the transmembrane domain 6 of human melanocortin-4 receptor","volume":"49","author":"Huang","year":"2012","journal-title":"J. Mol. Endocrinol."},{"key":"10.1016\/j.mce.2026.112876_bib58","doi-asserted-by":"crossref","first-page":"817","DOI":"10.7150\/ijbs.9625","article-title":"A small molecule agonist THIQ as a novel pharmacoperone for intracellularly retained melanocortin-4 receptor mutants","volume":"10","author":"Huang","year":"2014","journal-title":"Int. J. Biol. Sci."},{"key":"10.1016\/j.mce.2026.112876_bib59","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1016\/S0092-8674(00)81865-6","article-title":"Targeted disruption of the melanocortin-4 receptor results in obesity in mice","volume":"88","author":"Huszar","year":"1997","journal-title":"Cell"},{"key":"10.1016\/j.mce.2026.112876_bib60","doi-asserted-by":"crossref","first-page":"3255","DOI":"10.1210\/jcem.87.7.8582","article-title":"Rescue of hypogonadotropic hypogonadism-causing and manufactured GnRH receptor mutants by a specific protein-folding template: misrouted proteins as a novel disease etiology and therapeutic target","volume":"87","author":"Janovick","year":"2002","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"10.1016\/j.mce.2026.112876_bib61","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1016\/j.mce.2008.09.015","article-title":"Increased plasma membrane expression of human follicle-stimulating hormone receptor by a small molecule thienopyr(im)idine","volume":"298","author":"Janovick","year":"2009","journal-title":"Mol. Cell. Endocrinol."},{"key":"10.1016\/j.mce.2026.112876_bib62","doi-asserted-by":"crossref","first-page":"21030","DOI":"10.1073\/pnas.1315194110","article-title":"Restoration of testis function in hypogonadotropic hypogonadal mice harboring a misfolded GnRHR mutant by pharmacoperone drug therapy","volume":"110","author":"Janovick","year":"2013","journal-title":"Proc. Natl. Acad. Sci. U. S. A"},{"key":"10.1016\/j.mce.2026.112876_bib63","doi-asserted-by":"crossref","first-page":"8727","DOI":"10.3390\/ijms23158727","article-title":"Melanocortin-5 receptor: pharmacology and its regulation of energy metabolism","volume":"23","author":"Ji","year":"2022","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.mce.2026.112876_bib64","doi-asserted-by":"crossref","first-page":"1248","DOI":"10.3390\/biom13081248","article-title":"Divergent pharmacology and biased signaling of the four melanocortin-4 receptor isoforms in rainbow trout (Oncorhynchus mykiss)","volume":"13","author":"Ji","year":"2023","journal-title":"Biomolecules"},{"key":"10.1016\/j.mce.2026.112876_bib65","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1016\/bs.pmbts.2022.03.001","article-title":"Melanocortin-1 receptor mutations and pigmentation: insights from large animals","volume":"189","author":"Ji","year":"2022","journal-title":"Prog. Mol. Biol. Transl. Sci."},{"key":"10.1016\/j.mce.2026.112876_bib66","doi-asserted-by":"crossref","DOI":"10.1016\/j.pharmthera.2025.108804","article-title":"Biased signaling in drug discovery and precision medicine","volume":"268","author":"Ji","year":"2025","journal-title":"Pharmacol. Ther."},{"key":"10.1016\/j.mce.2026.112876_bib67","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1007\/s00360-017-1062-0","article-title":"Effects of melanocortin-4 receptor agonists and antagonists on expression of genes related to reproduction in spotted scat, Scatophagus argus","volume":"187","author":"Jiang","year":"2017","journal-title":"J. Comp. Physiol. B"},{"key":"10.1016\/j.mce.2026.112876_bib68","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1056\/NEJMoa1512693","article-title":"Proopiomelanocortin deficiency treated with a melanocortin-4 receptor agonist","volume":"375","author":"K\u00fchnen","year":"2016","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.mce.2026.112876_bib69","doi-asserted-by":"crossref","first-page":"490","DOI":"10.2337\/db12-0598","article-title":"Chronic treatment with a melanocortin-4 receptor agonist causes weight loss, reduces insulin resistance, and improves cardiovascular function in diet-induced obese rhesus macaques","volume":"62","author":"Kievit","year":"2013","journal-title":"Diabetes"},{"key":"10.1016\/j.mce.2026.112876_bib70","doi-asserted-by":"crossref","first-page":"478","DOI":"10.1021\/acsmedchemlett.3c00514","article-title":"Discovery of CRN04894: a novel potent selective MC2R antagonist","volume":"15","author":"Kim","year":"2024","journal-title":"ACS Med. Chem. Lett."},{"key":"10.1016\/j.mce.2026.112876_bib71","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1110\/ps.0213603","article-title":"Isolation and biochemical characterization of LEAP-2, a novel blood peptide expressed in the liver","volume":"12","author":"Krause","year":"2003","journal-title":"Protein Sci."},{"key":"10.1016\/j.mce.2026.112876_bib72","doi-asserted-by":"crossref","first-page":"1892","DOI":"10.1016\/j.peptides.2009.07.012","article-title":"Analysis of the therapeutic functions of novel melanocortin receptor agonists in MC3R- and MC4R-deficient C57BL\/6J mice","volume":"30","author":"Kumar","year":"2009","journal-title":"Peptides"},{"key":"10.1016\/j.mce.2026.112876_bib73","doi-asserted-by":"crossref","first-page":"768","DOI":"10.1161\/01.HYP.0000048194.97428.1A","article-title":"Hypothalamic melanocortin receptors and chronic regulation of arterial pressure and renal function","volume":"41","author":"Kuo","year":"2003","journal-title":"Hypertension"},{"key":"10.1016\/j.mce.2026.112876_bib74","doi-asserted-by":"crossref","first-page":"913","DOI":"10.1016\/S0140-6736(14)61375-1","article-title":"Cushing's syndrome","volume":"386","author":"Lacroix","year":"2015","journal-title":"Lancet"},{"key":"10.1016\/j.mce.2026.112876_bib75","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1038\/s41586-021-04088-9","article-title":"MC3R links nutritional state to childhood growth and the timing of puberty","volume":"599","author":"Lam","year":"2021","journal-title":"Nature"},{"key":"10.1016\/j.mce.2026.112876_bib76","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1056\/NEJMoa1411481","article-title":"Afamelanotide for erythropoietic protoporphyria","volume":"373","author":"Langendonk","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.mce.2026.112876_bib77","doi-asserted-by":"crossref","first-page":"3181","DOI":"10.1021\/jm9017866","article-title":"Discovery of a selective small-molecule melanocortin-4 receptor agonist with efficacy in a pilot study of sexual dysfunction in humans","volume":"53","author":"Lansdell","year":"2010","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.mce.2026.112876_bib78","doi-asserted-by":"crossref","first-page":"2730","DOI":"10.1001\/jama.1991.03470190078033","article-title":"Induction of skin tanning by subcutaneous administration of a potent synthetic melanotropin","volume":"266","author":"Levine","year":"1991","journal-title":"JAMA"},{"key":"10.1016\/j.mce.2026.112876_bib79","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1016\/j.ygcen.2016.04.010","article-title":"Molecular cloning, tissue distribution, and pharmacological characterization of melanocortin-4 receptor in spotted scat","volume":"230\u2013231","author":"Li","year":"2016","journal-title":"Scatophagus argus. Gen Comp Endocrinol."},{"key":"10.1016\/j.mce.2026.112876_bib80","doi-asserted-by":"crossref","first-page":"7438","DOI":"10.1021\/acs.jmedchem.2c00123","article-title":"Peptidomimetics: an overview of recent medicinal chemistry efforts toward the discovery of novel small molecule inhibitors","volume":"65","author":"Li Petri","year":"2022","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.mce.2026.112876_bib81","doi-asserted-by":"crossref","first-page":"5231","DOI":"10.1016\/j.ymthe.2025.07.046","article-title":"Intercepting the complement amplification loop through podocyte MC5R signaling ameliorates membranous nephropathy","volume":"33","author":"Liu","year":"2025","journal-title":"Mol. Ther."},{"key":"10.1016\/j.mce.2026.112876_bib82","doi-asserted-by":"crossref","first-page":"5537","DOI":"10.1021\/acs.chemrev.8b00532","article-title":"Folding and misfolding of human membrane proteins in health and disease: from single molecules to cellular proteostasis","volume":"119","author":"Marinko","year":"2019","journal-title":"Chem. Rev."},{"key":"10.1016\/j.mce.2026.112876_bib83","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1007\/s40265-021-01470-9","article-title":"Setmelanotide: first approval","volume":"81","author":"Markham","year":"2021","journal-title":"Drugs"},{"key":"10.1016\/j.mce.2026.112876_bib84","doi-asserted-by":"crossref","first-page":"2766","DOI":"10.1210\/en.2005-0142","article-title":"The regulation of feeding and metabolic rate and the prevention of murine cancer cachexia with a small-molecule melanocortin-4 receptor antagonist","volume":"146","author":"Markison","year":"2005","journal-title":"Endocrinology"},{"key":"10.1016\/j.mce.2026.112876_bib85","first-page":"1432","article-title":"Role of the central melanocortin system in cachexia","volume":"61","author":"Marks","year":"2001","journal-title":"Cancer Res."},{"key":"10.1016\/j.mce.2026.112876_bib86","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1210\/rp.56.1.359","article-title":"Central melanocortins and the regulation of weight during acute and chronic disease","volume":"56","author":"Marks","year":"2001","journal-title":"Recent Prog. Horm. Res."},{"key":"10.1016\/j.mce.2026.112876_bib87","doi-asserted-by":"crossref","first-page":"1939","DOI":"10.1016\/j.bbadis.2013.06.006","article-title":"Activation of MAPK by inverse agonists in six naturally occurring constitutively active mutant human melanocortin-4 receptors","volume":"1832","author":"Mo","year":"2013","journal-title":"Biochim. Biophys. Acta"},{"key":"10.1016\/j.mce.2026.112876_bib88","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1111\/j.1749-6632.2003.tb03167.x","article-title":"PT-141: a melanocortin agonist for the treatment of sexual dysfunction","volume":"994","author":"Molinoff","year":"2003","journal-title":"Ann. N. Y. Acad. Sci."},{"key":"10.1016\/j.mce.2026.112876_bib89","doi-asserted-by":"crossref","first-page":"3381","DOI":"10.4049\/jimmunol.1402645","article-title":"Biased agonism as a novel strategy to harness the proresolving properties of melanocortin receptors without eliciting melanogenic effects","volume":"194","author":"Montero-Melendez","year":"2015","journal-title":"J. Immunol."},{"key":"10.1016\/j.mce.2026.112876_bib90","doi-asserted-by":"crossref","first-page":"887","DOI":"10.1172\/JCI8688","article-title":"Pharmacological chaperones rescue cell-surface expression and function of misfolded V2 vasopressin receptor mutants","volume":"105","author":"Morello","year":"2000","journal-title":"J. Clin. Investig."},{"key":"10.1016\/j.mce.2026.112876_bib91","doi-asserted-by":"crossref","first-page":"7172","DOI":"10.1073\/pnas.1015723108","article-title":"Rescue of expression and signaling of human luteinizing hormone G protein-coupled receptor mutants with an allosterically binding small-molecule agonist","volume":"108","author":"Newton","year":"2011","journal-title":"Proc. Natl. Acad. Sci. U. S. A"},{"key":"10.1016\/j.mce.2026.112876_bib92","doi-asserted-by":"crossref","first-page":"771","DOI":"10.1124\/jpet.105.097725","article-title":"Peripheral administration of a melanocortin 4-receptor inverse agonist prevents loss of lean body mass in tumor-bearing mice","volume":"317","author":"Nicholson","year":"2006","journal-title":"J. Pharmacol. Exp. Therapeut."},{"key":"10.1016\/j.mce.2026.112876_bib93","doi-asserted-by":"crossref","first-page":"14442","DOI":"10.1074\/jbc.M300087200","article-title":"Pharmacological chaperone-mediated in vivo folding and stabilization of the P23H-opsin mutant associated with autosomal dominant retinitis pigmentosa","volume":"278","author":"Noorwez","year":"2003","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.mce.2026.112876_bib94","doi-asserted-by":"crossref","DOI":"10.1016\/j.bcp.2023.115952","article-title":"Melanocortin receptor 4 as a new target in melanoma therapy: anticancer activity of the inhibitor ML00253764 alone and in association with B-raf inhibitor vemurafenib","volume":"219","author":"Orlandi","year":"2024","journal-title":"Biochem. Pharmacol."},{"key":"10.1016\/j.mce.2026.112876_bib95","doi-asserted-by":"crossref","first-page":"4464","DOI":"10.1016\/j.bmcl.2007.06.010","article-title":"Identification of a novel series of benzimidazoles as potent and selective antagonists of the human melanocortin-4 receptor","volume":"17","author":"Poitout","year":"2007","journal-title":"Bioorg. Med. Chem. Lett"},{"key":"10.1016\/j.mce.2026.112876_bib96","doi-asserted-by":"crossref","first-page":"4615","DOI":"10.1016\/j.bmcl.2005.06.058","article-title":"Optimization of piperazinebenzylamines with a N-(1-methoxy-2-propyl) side chain as potent and selective antagonists of the human melanocortin-4 receptor","volume":"15","author":"Pontillo","year":"2005","journal-title":"Bioorg. Med. Chem. Lett"},{"key":"10.1016\/j.mce.2026.112876_bib97","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.132778","article-title":"Pharmacological chaperone action in humanized mouse models of MC4R-linked obesity","volume":"6","author":"Rene","year":"2021","journal-title":"JCI Insight"},{"key":"10.1016\/j.mce.2026.112876_bib98","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1124\/jpet.110.172098","article-title":"Pharmacological chaperones restore function to MC4R mutants responsible for severe early-onset obesity","volume":"335","author":"Rene","year":"2010","journal-title":"J. Pharmacol. Exp. Therapeut."},{"key":"10.1016\/j.mce.2026.112876_bib99","doi-asserted-by":"crossref","first-page":"560","DOI":"10.3389\/fphar.2018.00560","article-title":"Binding, thermodynamics, and selectivity of a non-peptide antagonist to the melanocortin-4 receptor","volume":"9","author":"Saleh","year":"2018","journal-title":"Front Pharmacol."},{"key":"10.1016\/j.mce.2026.112876_bib100","doi-asserted-by":"crossref","first-page":"21729","DOI":"10.1021\/acs.jmedchem.4c02358","article-title":"Discovery of MT-7117 (Dersimelagon phosphoric acid): a novel, potent, selective, and nonpeptidic orally available melanocortin 1 receptor agonist","volume":"67","author":"Sato","year":"2024","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.mce.2026.112876_bib101","doi-asserted-by":"crossref","first-page":"5754","DOI":"10.1073\/pnas.77.10.5754","article-title":"4-Norleucine, 7-D-phenylalanine-\u03b1-melanocyte-stimulating hormone: a highly potent \u03b1-melanotropin with ultralong biological activity","volume":"77","author":"Sawyer","year":"1980","journal-title":"Proc. Natl. Acad. Sci. U. S. A"},{"key":"10.1016\/j.mce.2026.112876_bib102","doi-asserted-by":"crossref","first-page":"1079","DOI":"10.1038\/s41591-021-01391-w","article-title":"Danuglipron (PF-06882961) in type 2 diabetes: a randomized, placebo-controlled, multiple ascending-dose phase 1 trial","volume":"27","author":"Saxena","year":"2021","journal-title":"Nat. Med."},{"key":"10.1016\/j.mce.2026.112876_bib103","doi-asserted-by":"crossref","first-page":"4589","DOI":"10.1021\/jm025539h","article-title":"Design and pharmacology of N-[(3R)-1,2,3,4-tetrahydroisoquinolinium- 3-ylcarbonyl]-(1R)-1-(4-chlorobenzyl)- 2-[4-cyclohexyl-4-(1H-1,2,4-triazol- 1-ylmethyl)piperidin-1-yl]-2-oxoethylamine (1), a potent, selective, melanocortin subtype-4 receptor agonist","volume":"45","author":"Sebhat","year":"2002","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.mce.2026.112876_bib104","article-title":"Dual activation of MC3R and MC4R drives weight loss and reduces food intake in obese primates","author":"Seiler","year":"2025","journal-title":"bioRxiv"},{"key":"10.1016\/j.mce.2026.112876_bib105","doi-asserted-by":"crossref","first-page":"2187","DOI":"10.1056\/NEJMoa2004325","article-title":"Oral Relugolix for androgen-deprivation therapy in advanced prostate cancer","volume":"382","author":"Shore","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.mce.2026.112876_bib106","doi-asserted-by":"crossref","first-page":"2747","DOI":"10.1021\/jm301253y","volume":"56","author":"Singh","year":"2013","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.mce.2026.112876_bib107","doi-asserted-by":"crossref","DOI":"10.1002\/ski2.78","article-title":"Melanogenic effect of dersimelagon (MT-7117), a novel oral melanocortin 1 receptor agonist","volume":"2","author":"Suzuki","year":"2022","journal-title":"Skin Health Dis"},{"key":"10.1016\/j.mce.2026.112876_bib108","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1210\/en.2008-0721","article-title":"Functional characterization and structural modeling of obesity associated mutations in the melanocortin 4 receptor","volume":"150","author":"Tan","year":"2009","journal-title":"Endocrinology"},{"key":"10.1016\/j.mce.2026.112876_bib109","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.mce.2005.04.012","article-title":"Molecular mechanisms of the neural melanocortin receptor dysfunction in severe early onset obesity","volume":"239","author":"Tao","year":"2005","journal-title":"Mol. Cell. Endocrinol."},{"key":"10.1016\/j.mce.2026.112876_bib110","doi-asserted-by":"crossref","first-page":"949","DOI":"10.1016\/j.pharmthera.2006.02.008","article-title":"Inactivating mutations of G protein-coupled receptors and diseases: Structure-function insights and therapeutic implications","volume":"111","author":"Tao","year":"2006","journal-title":"Pharmacol. Ther."},{"key":"10.1016\/j.mce.2026.112876_bib111","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1016\/S1877-1173(09)88006-X","article-title":"Mutations in melanocortin-4 receptor and human obesity","volume":"88","author":"Tao","year":"2009","journal-title":"Prog. Mol. Biol. Transl. Sci."},{"key":"10.1016\/j.mce.2026.112876_bib112","doi-asserted-by":"crossref","first-page":"506","DOI":"10.1210\/er.2009-0037","article-title":"The melanocortin-4 receptor: physiology, pharmacology, and pathophysiology","volume":"31","author":"Tao","year":"2010","journal-title":"Endocr. Rev."},{"key":"10.1016\/j.mce.2026.112876_bib113","doi-asserted-by":"crossref","first-page":"2411","DOI":"10.1016\/j.bbadis.2017.08.001","article-title":"Melanocortin receptors","volume":"1863","author":"Tao","year":"2017","journal-title":"Biochim. Biophys. Acta Mol. Basis Dis."},{"key":"10.1016\/j.mce.2026.112876_bib114","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1016\/bs.pmbts.2022.03.003","article-title":"Mutations in melanocortin-4 receptor: from fish to men","volume":"189","author":"Tao","year":"2022","journal-title":"Prog. Mol. Biol. Transl. Sci."},{"key":"10.1016\/j.mce.2026.112876_bib115","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1016\/B978-0-12-381298-8.00014-9","article-title":"Constitutive activity of neural melanocortin receptors","volume":"484","author":"Tao","year":"2010","journal-title":"Methods Enzymol."},{"key":"10.1016\/j.mce.2026.112876_bib116","doi-asserted-by":"crossref","first-page":"602","DOI":"10.1210\/er.2013-1121","article-title":"Chaperoning G protein-coupled receptors: from cell biology to therapeutics","volume":"35","author":"Tao","year":"2014","journal-title":"Endocr. Rev."},{"key":"10.1016\/j.mce.2026.112876_bib117","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1152\/physrev.00029.2016","article-title":"Pharmacoperones as novel therapeutics for diverse protein conformational diseases","volume":"98","author":"Tao","year":"2018","journal-title":"Physiol. Rev."},{"key":"10.1016\/j.mce.2026.112876_bib118","doi-asserted-by":"crossref","first-page":"131","DOI":"10.3389\/fendo.2014.00131","article-title":"Ipsen 5i is a novel potent pharmacoperone for intracellularly retained melanocortin-4 receptor mutants","volume":"5","author":"Tao","year":"2014","journal-title":"Front Endocrinol (Lausanne)"},{"key":"10.1016\/j.mce.2026.112876_bib119","doi-asserted-by":"crossref","first-page":"4544","DOI":"10.1210\/en.2003-0524","article-title":"Functional characterization of melanocortin-4 receptor mutations associated with childhood obesity","volume":"144","author":"Tao","year":"2003","journal-title":"Endocrinology"},{"key":"10.1016\/j.mce.2026.112876_bib120","doi-asserted-by":"crossref","DOI":"10.1210\/jendso\/bvaf149.143","article-title":"SAT-711 Efficacy and safety of once-daily oral bivamelagon in acquire hypothalamic obesity: Results from a double-blind, multi center, placebo-controlled, randomized Phase 2 trial","author":"Thaker","year":"2025","journal-title":"J. Endocr. Soc."},{"key":"10.1016\/j.mce.2026.112876_bib121","doi-asserted-by":"crossref","first-page":"1068","DOI":"10.2174\/156802607780906609","article-title":"Small molecule ligands of the human melanocortin-4 receptor","volume":"7","author":"Ujjainwalla","year":"2007","journal-title":"Curr. Top. Med. Chem."},{"key":"10.1016\/j.mce.2026.112876_bib122","doi-asserted-by":"crossref","first-page":"4984","DOI":"10.1007\/s12035-017-0702-4","article-title":"Melanocortin receptor-4 and glioblastoma cells: effects of the selective antagonist ML00253764 alone and in combination with temozolomide in vitro and in vivo","volume":"55","author":"Vaglini","year":"2018","journal-title":"Mol. Neurobiol."},{"key":"10.1016\/j.mce.2026.112876_bib123","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1038\/2407","article-title":"A frameshift mutation in human MC4R is associated with a dominant form of obesity","volume":"20","author":"Vaisse","year":"1998","journal-title":"Nat. Genet."},{"key":"10.1016\/j.mce.2026.112876_bib124","doi-asserted-by":"crossref","first-page":"11381","DOI":"10.1073\/pnas.172378699","article-title":"A role for the melanocortin 4 receptor in sexual function","volume":"99","author":"Van der Ploeg","year":"2002","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.mce.2026.112876_bib125","doi-asserted-by":"crossref","first-page":"2302","DOI":"10.1016\/j.bmcl.2006.01.016","article-title":"Identification and structure-activity relationships of a new series of Melanocortin-4 receptor antagonists","volume":"16","author":"Vos","year":"2006","journal-title":"Bioorg. Med. Chem. Lett"},{"key":"10.1016\/j.mce.2026.112876_bib126","doi-asserted-by":"crossref","first-page":"1602","DOI":"10.1021\/jm034244g","article-title":"Identification of 2-[2-[2-(5-bromo-2- methoxyphenyl)-ethyl]-3-fluorophenyl]-4,5-dihydro-1H-imidazole (ML00253764), a small molecule melanocortin 4 receptor antagonist that effectively reduces tumor-induced weight loss in a mouse model","volume":"47","author":"Vos","year":"2004","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.mce.2026.112876_bib127","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1016\/j.bcp.2008.05.026","article-title":"Functions of acidic transmembrane residues in human melanocortin-3 receptor binding and activation","volume":"76","author":"Wang","year":"2008","journal-title":"Biochem. Pharmacol."},{"key":"10.1016\/j.mce.2026.112876_bib128","doi-asserted-by":"crossref","first-page":"683","DOI":"10.3389\/fendo.2019.00683","article-title":"Melanocortin regulation of inflammation","volume":"10","author":"Wang","year":"2019","journal-title":"Front Endocrinol (Lausanne)"},{"key":"10.1016\/j.mce.2026.112876_bib129","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1530\/JME-14-0005","article-title":"Rescue of defective MC4R cell-surface expression and signaling by a novel pharmacoperone Ipsen 17","volume":"53","author":"Wang","year":"2014","journal-title":"J. Mol. Endocrinol."},{"key":"10.1016\/j.mce.2026.112876_bib130","doi-asserted-by":"crossref","first-page":"1325","DOI":"10.1001\/jama.2025.14913","article-title":"Rewriting the chapter on cystic fibrosis: the 2025 Lasker-DeBakey Clinical Medical Research Award","volume":"334","author":"Welsh","year":"2025","journal-title":"JAMA"},{"key":"10.1016\/j.mce.2026.112876_bib131","doi-asserted-by":"crossref","first-page":"1251","DOI":"10.1016\/0092-8674(93)90353-R","article-title":"Molecular mechanisms of CFTR chloride channel dysfunction in cystic fibrosis","volume":"73","author":"Welsh","year":"1993","journal-title":"Cell."},{"key":"10.1016\/j.mce.2026.112876_bib132","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1016\/S0022-5347(01)62903-3","article-title":"Synthetic melanotropic peptide initiates erections in men with psychogenic erectile dysfunction: double-blind, placebo controlled crossover study","volume":"160","author":"Wessells","year":"1998","journal-title":"J. Urol."},{"key":"10.1016\/j.mce.2026.112876_bib133","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1111\/j.1749-6632.2003.tb03166.x","article-title":"MT-II induces penile erection via brain and spinal mechanisms","volume":"994","author":"Wessells","year":"2003","journal-title":"Ann. N. Y. Acad. Sci."},{"key":"10.1016\/j.mce.2026.112876_bib134","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0004774","article-title":"Orally available selective melanocortin-4 receptor antagonists stimulate food intake and reduce cancer-induced cachexia in mice","volume":"4","author":"Weyermann","year":"2009","journal-title":"PLos One"},{"key":"10.1016\/j.mce.2026.112876_bib135","doi-asserted-by":"crossref","first-page":"3292","DOI":"10.1210\/endo.142.8.8324","article-title":"Reversal of cancer anorexia by blockade of central melanocortin receptors in rats","volume":"142","author":"Wisse","year":"2001","journal-title":"Endocrinology"},{"key":"10.1016\/j.mce.2026.112876_bib136","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1111\/j.1749-6632.2003.tb03190.x","article-title":"Melanocortin signaling and anorexia in chronic disease states","volume":"994","author":"Wisse","year":"2003","journal-title":"Ann. N. Y. Acad. Sci."},{"key":"10.1016\/j.mce.2026.112876_bib137","doi-asserted-by":"crossref","first-page":"3831","DOI":"10.1007\/s00018-020-03511-0","article-title":"Melanocortin 5 receptor signaling pathway in health and disease","volume":"77","author":"Xu","year":"2020","journal-title":"Cell. Mol. Life Sci."},{"key":"10.1016\/j.mce.2026.112876_bib138","doi-asserted-by":"crossref","first-page":"1085","DOI":"10.1126\/science.abj2674","article-title":"Pituitary hormone alpha-MSH promotes tumor-induced myelopoiesis and immunosuppression","volume":"377","author":"Xu","year":"2022","journal-title":"Science"},{"key":"10.1016\/j.mce.2026.112876_bib139","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1016\/j.regpep.2009.03.006","article-title":"Key amino acid residues in the melanocortin-4 receptor for nonpeptide THIQ specific binding and signaling","volume":"155","author":"Yang","year":"2009","journal-title":"Regul. Pept."},{"key":"10.1016\/j.mce.2026.112876_bib140","doi-asserted-by":"crossref","DOI":"10.1016\/j.mce.2020.110929","article-title":"Biased signaling in fish melanocortin-4 receptors (MC4Rs): divergent pharmacology of four ligands on spotted scat (Scatophagus argus) and grass carp (Ctenopharyngodon idella) MC4Rs","volume":"515","author":"Yang","year":"2020","journal-title":"Mol. Cell. Endocrinol."},{"key":"10.1016\/j.mce.2026.112876_bib141","doi-asserted-by":"crossref","first-page":"2486","DOI":"10.1016\/j.bbadis.2017.04.010","article-title":"Biased signaling at neural melanocortin receptors in regulation of energy homeostasis","volume":"1863","author":"Yang","year":"2017","journal-title":"Biochim. Biophys. Acta Mol. Basis Dis."},{"key":"10.1016\/j.mce.2026.112876_bib142","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1016\/bs.pmbts.2016.01.002","article-title":"Mutations in melanocortin-3 receptor gene and human obesity","volume":"140","author":"Yang","year":"2016","journal-title":"Prog. Mol. Biol. Transl. Sci."},{"key":"10.1016\/j.mce.2026.112876_bib143","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1038\/2404","article-title":"A frameshift mutation in MC4R associated with dominantly inherited human obesity","volume":"20","author":"Yeo","year":"1998","journal-title":"Nat. Genet."},{"key":"10.1016\/j.mce.2026.112876_bib144","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1016\/j.gene.2018.07.056","article-title":"Melanocortin-4 receptor in swamp eel (Monopterus albus): cloning, tissue distribution, and pharmacology","volume":"678","author":"Yi","year":"2018","journal-title":"Gene"},{"key":"10.1016\/j.mce.2026.112876_bib145","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1186\/s12974-021-02078-2","article-title":"Activation of MC1R with BMS-470539 attenuates neuroinflammation via cAMP\/PKA\/Nurr1 pathway after neonatal hypoxic-ischemic brain injury in rats","volume":"18","author":"Yu","year":"2021","journal-title":"J. Neuroinflammation"},{"key":"10.1016\/j.mce.2026.112876_bib146","doi-asserted-by":"crossref","first-page":"1163","DOI":"10.1038\/s41422-021-00552-3","article-title":"Structural insights into ligand recognition and activation of the melanocortin-4 receptor","volume":"31","author":"Zhang","year":"2021","journal-title":"Cell Res."},{"key":"10.1016\/j.mce.2026.112876_bib147","article-title":"Hypothalamic-pituitary-derived melanocortin axis links to myelopoiesis and immunotherapy","volume":"4","author":"Zhang","year":"2023","journal-title":"Innovation (Camb)"},{"key":"10.1016\/j.mce.2026.112876_bib148","doi-asserted-by":"crossref","first-page":"4921","DOI":"10.1172\/JCI138392","article-title":"Melanocortin-4 receptor antagonist TCMCB07 ameliorates cancer- and chronic kidney disease-associated cachexia","volume":"130","author":"Zhu","year":"2020","journal-title":"J. Clin. Investig."},{"key":"10.1016\/j.mce.2026.112876_bib149","article-title":"Melanocortin-4 receptor antagonist TCMCB07 alleviates chemotherapy-induced anorexia and weight loss in rats","volume":"135","author":"Zhu","year":"2024","journal-title":"J. Clin. Investig."}],"container-title":["Molecular and Cellular Endocrinology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S030372072600153X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S030372072600153X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,8,7]],"date-time":"2026-08-07T14:32:33Z","timestamp":1786113153000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S030372072600153X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,11]]},"references-count":149,"alternative-id":["S030372072600153X"],"URL":"https:\/\/doi.org\/10.1016\/j.mce.2026.112876","relation":{},"ISSN":["0303-7207"],"issn-type":[{"value":"0303-7207","type":"print"}],"subject":[],"published":{"date-parts":[[2026,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Small molecule ligands for the melanocortin-4 receptor: pharmacology, biased signaling, and pharmacoperone potential","name":"articletitle","label":"Article Title"},{"value":"Molecular and Cellular Endocrinology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.mce.2026.112876","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"112876"}}